10-Q · May 8, 2026
Nu Skin Enterprises reported Q1 2026 results showing a revenue decline of 12.0% year-over-year to $320.6 million, and a significant drop in EPS to $0.04 from $2.14 in the same period last year. The company's adjusted…
Earnings analysis · 10-Q
NUS earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Nu Skin’s Q2 revenue was $320.112 million, approximately 17.1% below the $386 million reported in Q2 2025 and 7.3% below consensus, while adjusted EPS of $0.20 matched expectations. GAAP EPS was negative $5.14 because…
Read full summary
Nu Skin’s Q2 revenue was $320.112 million, approximately 17.1% below the $386 million reported in Q2 2025 and 7.3% below consensus, while adjusted EPS of $0.20 matched expectations. GAAP EPS was negative $5.14 because of a $78.875 million impairment charge. Management lowered FY2026 revenue guidance to $1.28-$1.35 billion and adjusted EPS guidance to $0.70-$0.90, and the company drew $30 million on its revolver, bringing the balance to $70 million.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-5.14
What stood out
-
Revenue Fell 17.1% Year Over Year
Q2 revenue was $320.112 million, down from $386 million in Q2 2025, a decrease of approximately 17.1%, and missed the $345.2 million consensus estimate by 7.3%.
-
Adjusted EPS Met Consensus
GAAP EPS was negative $5.14, primarily reflecting a $78.875 million impairment charge. Adjusted EPS was $0.20, matching the $0.20 consensus estimate.
-
Revolver Draw Increased Liquidity Support
The company drew $30 million under its revolving credit facility on August 6, 2026, bringing the total revolving-credit balance to $70 million as of the filing date.
-
Planned $25 Million Debt Repayment
Management anticipates repaying approximately $25 million during the third quarter of 2026, implying a potential reduction of the stated revolving-credit balance to approximately $45 million if completed.
What to watch
-
Large Impairment Depressed GAAP Earnings
The $78.875 million impairment charge drove GAAP EPS to negative $5.14 in Q2, highlighting continued pressure on asset values and reported profitability.
-
Lowered Full-Year Outlook
FY2026 revenue guidance was reduced to $1.28-$1.35 billion from $1.35-$1.50 billion, while adjusted EPS guidance was reduced to $0.70-$0.90 from $0.70-$1.10.
-
Higher Revolving-Credit Balance
The company had $70 million outstanding under its revolving credit facility as of the filing date after a $30 million draw, creating added refinancing and liquidity exposure despite the anticipated $25 million Q3 repayment.
-
Foreign-Exchange Exposure
The filing states that a majority of revenue and many expenses are recognized outside the United States, and that a strengthening U.S. dollar negatively affects reported revenue and earnings. Argentina represented less than 4% of consolidated net sales for the six months ended June 30, 2026.
-
No Material Risk-Factor Changes
The filing reports no material changes from the risk factors disclosed in the 2025 Form 10-K; however, the company continues to describe potentially significant currency sensitivity because a large portion of its business is outside the United States.
Management's outlook
FY2026 adjusted EPS guidance was lowered to $0.70-$0.90 from $0.70-$1.10; FY2026 revenue guidance was lowered to $1.28-$1.35 billion from $1.35-$1.50 billion. Q3 adjusted EPS guidance is $0.10-$0.20.
Earlier filings 4
10-K · February 13, 2026
Nu Skin Enterprises Inc. (NUS) experienced a significant decline in revenue and customer metrics in 2025 due to ongoing global macroeconomic challenges that continued to dampen consumer spending. Revenue dropped 14% to…
10-Q · November 7, 2025
Nu Skin Enterprises, Inc. reported a challenging third quarter in 2025, with revenues of $364.2 million, down 15% from $430.1 million year-over-year. However, earnings per share increased to $0.34 due to lower expenses…
10-Q · August 8, 2025
Nu Skin Enterprises, Inc. reported Q2 revenues of $386.1 million, a decline of 12% year-over-year, but better than analysts' expectations, with reported EPS of $0.43 compared to a loss of $2.38 in the prior year. While…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.